Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Co-Receptor Tropism Assay Launched for HIV Patients

By HospiMedica staff writers
Posted on 29 Aug 2007
The human immunodeficiency virus (HIV) diagnostic co-receptor tropism assay has been launched for patients in the United States.

Called Trofile, the assay determines which co-receptor a patient's HIV strain or strains use for viral entry--CCR5, CXCR4, or a combination of CCR5 and CXCR4. More...
The cellular gateways that a particular HIV strain uses to gain entry into a healthy CD4+ cell is known as the patient's tropism.

Trofile amplifies a patient's HIV genome (from his/her blood sample) to make HIV particles specific to that individual patient. The resultant HIV particles are then used to infect CCR5- and CXCR4- expressing cell lines. Once the virus infects the cell and undergoes its single round of replication, a reporter gene expresses its indicator gene (luciferase), giving a visible signal-thus identifying the patient's viral tropism. Viral load must be at least 1,000 copies/ml to determine a patient's viral tropism.

Monogram (San Francisco, CA, USA) announced the commercial introduction of its Trofile assay following the announcement that Pfizer
(New York, NY, USA) received US Food and Drug Administration (FDA) approval of a novel HIV therapy, Selzentry (maraviroc), a CCR% antagonist. Trofile was the test used for patient selection for Selzentry's clinical development program and the two companies are engaged in a collaboration agreement to make Monogram's assay available for patient use globally.

Selzentry has been approved for the combination antiretroviral treatment of adults infected with only CCR5-tropic HIV-1 who have evidence of viral replication and have HIV-1 strains resistant to multiple antiretroviral agents. The FDA-approved label requires that tropism testing to identify patients infected with R5 virus guide the use of Selzentry.

Trofile is a vital new tool that helps physicians make the most informed treatment decisions for their patients living with HIV. Combined with Pfizer's new therapy, this represents a major milestone in the treatment of HIV, said Monogram CEO Bill Young. [The] approval also marks an important landmark in personalized medicine as the healthcare community shifts to treat patients individually by combining powerful diagnostic tools with drug therapies to better predict an individual patient's response.


Related Links:
Monogram
Pfizer

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Infant Resuscitator
Easypuff
Imaging Table
Stille imagiQ2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.